THE EFFECT OF ASPIRIN AND TICLOPIDINE ON LIVER FUNCTION TEST IN RATS

Z. Stanojević ,
Z. Stanojević

Institute of Pharmacology and toxicology, Medical faculty , Priština, Kosovska Mitrovica

R. Mitić ,
R. Mitić

Institute of Pharmacology and toxicology, Medical faculty , Priština, Kosovska Mitrovica

Z. Bukumirić ,
Z. Bukumirić

Institute of Pharmacology and toxicology, Medical faculty , Priština, Kosovska Mitrovica

M. Bursać ,
M. Bursać

Institute of Pharmacology and toxicology, Medical faculty , Priština, Kosovska Mitrovica

S. Baščarević ,
S. Baščarević

Institute of Pharmacology and toxicology, Medical faculty , Priština, Kosovska Mitrovica

J. Rašić
J. Rašić

Institute of Pharmacology and toxicology, Medical faculty , Priština, Kosovska Mitrovica

Published: 01.01.2004.

Volume 32, Issue 1 (2004)

pp. 7-10;

https://doi.org/10.70949/pramed200401059S

Abstract

The purpose of this study was to evaluate the effect of aspirin and ticlopidine, administered alone and in combination, on liver function parameters. The experiment was conducted on white laboratory rats, type Wistar. Thirty-two rats were divided in four groups and they recived one of the following treatments for 4 days: group I, control, saline (1 ml/kg, i.p.); group II, aspirin (50 mg/kg/day i.p.); group III, ticlopidine (125 mg/kg/day i.p.) and group IV, aspirin+ticlopidine combination (50 mg/kg/day+125 mg/kg/day i.p.). After the treatment the animals were anaesthetised with ether and blood for further analyses was taken by cardiopunction. The total cholesterol serum level was significantly increased only in ticlopidine group in comparison to control (p<0.01).Also, the serum activity of alkaline phosphatase and total bilirubin concentration were significantly elevated only in ticlopidine treated group (p<0.001). Serum AST and ALT activities were not significantly elevated in all treating groups. On basis of the obtained results it can be noticed that the values of liver function parameters are greater in group treated with ticlopidine than in group treated with ticlopidine and aspirin combination.

Keywords

References

1.
Varvello L, Arno C, Coggiola M, Ramassotto E, Pascale C. Cholestasis from Ticlopidine: Two Clinical Cases. Ann Ital Med Int. 17(4):252–5.
2.
Gregorini L, Marco J, Fajadet J. Ticlopidine and Acetylsalicylic Acid Pretreatment Reduce Coagulation and Platelet Activation During Coronary Dilatation Procedures. J Am Coll Cardiol. :28.
3.
E BM, O A, F D, P B, C D. Combination of Two Doses of Acetylsalicylic Acid: Experimental Study of Arterial Thrombus. Thrombosis Research. 90(5):215–21.
4.
Suehiro A, Oura Y, Meda M, Kakishita E. Correlation Between Bleeding Time and Antithrombotic Effects of Platelet-Suppressive Agents in a Rat Experimental Model. Res Comm Chem Pathol Pharmacol. 83(2):157–63.
5.
Tsai MH, Tsai SL, Chen TC, Liaw YF. Ticlopidine-Induced Cholestatic Hepatitis with Antinuclear Antibody in Serum. J Formos Med Assoc. 99(11):866–9.
6.
Freeland GR, Northington RS, Hedrich DA. Hepatic Safety of Two Analgesics Used Over the Counter: Ibuprofen and Aspirin. Clin Pharmacol Ther. 43:473–9.
7.
Alvaro D, Gigliozzi A, Gaudio E. Ticlopidine-Induced Cholestasis: Report of Two Cases and Experimental Evidence of the Drug’s Adverse Effect in Isolated Perfused Rat Liver. Eur J Gastroenterol Hepatol. 6:943–50.
8.
Valverde PR. Ticlopidine-Induced Granulomatous Hepatitis. Ann Pharmacother. 29(633).
9.
Trauner M, Meier PJ, Boyer JL. Molecular Pathogenesis of Cholestasis. N Engl J Med. 339:1217–27.
10.
Placci A, Melandri G, Cecilioni L, Valgimigli M, Bolondi L. Late-Appearing Cholestatic Icterus After a Month of Treatment with Ticlopidine. Ital Heart J. 2(11):1240–2.
11.
Antiplatelet Trialists Collaboration: Collaborative Overview of Randomised Trials of Antiplatelet Therapy: Prevention of Death, Myocardial Infarction, and Stroke by Prolongation of Antiplatelet Therapy in Various Categories of Patients. Br Med J. 308:81–106.
12.
Skurnik YD, Tcherniak A, Edlan K, Sthoeger Z. Ticlopidine-Induced Cholestatic Hepatitis. Ann Pharmacother. 37(3):371–5.
13.
Bošković B. Novosti u Terapiji: Pregled Literature o Lekovima za 2000. In: Godinu VMA, Institut za Naučne Informacije Informativni Bilten.
14.
Kažić T, Farmakologija FK. Treće Izdanje. Integra. :231–4.
15.
Donnan GA. Davis SM: Aspirin Therapy Should Be First-Line. Stroke. 33:2139–40.
16.
Diener HC. Aspirin Therapy Should Be First-Line Treatment in Secondary Prevention of Stroke - Again. Stroke. 33:2138–9.
17.
Warlow C. Aspirin Should Be First-Line Antiplatelet Therapy in the Secondary Prevention of Stroke. Stroke. 33:2137–8.
18.
Gent M, Blacely J, Easton J. The Canadian American Ticlopidine Study in Tromboembolic Stroke. Lancet. :1215–20.
19.
Hass WK, Easton JD, HP A, Pryse PW, Molony BA, Anderson S, et al. A Randomized Trial Comparing Ticlopidine Hydrochloride with Aspirin for the Prevention of Stroke in High-Risk Patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 321:501–7.
20.
Patrono C. Drug Therapy: Aspirin as an Antiplatelet Drug. N Engl J Med. 330:1287–94.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by